Scribe projected to enter the clinic in mid-2026 with STX-1150, a PCSK9-targeting CRISPR epigenetic silencing therapy for durable LDL-C reduction ...
A high throughput screen of >30,000 diverse repressor domains from across the tree of life identifies repressor domains with unique structures that underpin enhanced epigenetic effector domain potency ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results